29 July 2014
A new study from the Thomas Jefferson University has pointed to a new course of action after surgery for patients recovering from prostate cancer.
The analysis uses genomic tools to help doctors and patients gauge the aggression of the cancer, allowing them to make a more informed decision.
First author Dr Robert Den, assistant professor of radiation oncology and cancer biology at Thomas Jefferson University, said medicine is moving away from treating everyone in the same way.
According to the expert, genomic tools allow doctors to see which cancers should be treated earlier with radiation, and which are unlikely to benefit from additional therapy.
Currently, around half of patients deemed to be at a high risk ever develop metastases, potentially wasting resources.
The test, called Decipher, generates a gene signature from a patient's cancer tissue sample and, based on this, the test determines whether the patient is at a high, intermediate or low risk of cancer recurrence and metastases.
Using medical records of 139 prostate cancer patients, the researchers grouped the patients by the treatments they received after surgery, and matched their records to the results of the genomic analysis.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.